Possible new Chemo for C-kit, VEGF, KRAS and EGFR cancers approved by FDA-regorafenib

› Forums › General Melanoma Community › Possible new Chemo for C-kit, VEGF, KRAS and EGFR cancers approved by FDA-regorafenib

  • Post
    • October 26, 2012 at 10:00 am
    JerryfromFauq
    Participant

      http://www.multivu.com/mnr/57608-bayer-regorafeni

      Bayer’s Stivarga® (regorafenib) Tablets Approved by U.S. FDA for Treatment of Metastatic Colorectal Cancer

      Wayne, NJ, and South San Francisco, CA, September 27, 2012 /PRNewswire/ — Bayer HealthCare and Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) announced today that the U.S. Food and Drug Administration (FDA) approved Bayer’s Stivarga® (regorafenib) tablets for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with currently available therapies (including fluoropyrimidine–, oxaliplatin– and irinotecan–based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy).1 The approval of Stivarga is based on results from the pivotal Phase III study (CORRECT) that demonstrated improvement in overall survival (OS) and progression-free survival (PFS) compared to placebo in patients with mCRC whose disease had progressed after approved standard therapies.2, 3

    Viewing 2 reply threads
    • Replies
        • October 26, 2012 at 10:16 am
        JerryfromFauq
        Participant

          Maybe I can get this past the filter!

             

          ESMO: Regorafenib Improved PFS for GIST in Post-Imatinib/Sunitsinib Setting.

          By Leah Lawrence | October 22, 2012
          Treatment of gastrointestinal stromal tumor (GIST) with regorafenib after prior treatment failure with both (Gleevec) Imatinib and sunitinib resulted in a progression-free survival (PFS) benefit for patients across all prespecified subgroups, according to a study presented recently at the European Society for Medical Oncology 2012 Congress. The results also showed that patients who were continued on the drug, even after disease progression, had an additional PFS benefit.
          • October 26, 2012 at 10:16 am
          JerryfromFauq
          Participant

            Maybe I can get this past the filter!

               

            ESMO: Regorafenib Improved PFS for GIST in Post-Imatinib/Sunitsinib Setting.

            By Leah Lawrence | October 22, 2012
            Treatment of gastrointestinal stromal tumor (GIST) with regorafenib after prior treatment failure with both (Gleevec) Imatinib and sunitinib resulted in a progression-free survival (PFS) benefit for patients across all prespecified subgroups, according to a study presented recently at the European Society for Medical Oncology 2012 Congress. The results also showed that patients who were continued on the drug, even after disease progression, had an additional PFS benefit.
            • October 26, 2012 at 10:16 am
            JerryfromFauq
            Participant

              Maybe I can get this past the filter!

                 

              ESMO: Regorafenib Improved PFS for GIST in Post-Imatinib/Sunitsinib Setting.

              By Leah Lawrence | October 22, 2012
              Treatment of gastrointestinal stromal tumor (GIST) with regorafenib after prior treatment failure with both (Gleevec) Imatinib and sunitinib resulted in a progression-free survival (PFS) benefit for patients across all prespecified subgroups, according to a study presented recently at the European Society for Medical Oncology 2012 Congress. The results also showed that patients who were continued on the drug, even after disease progression, had an additional PFS benefit.
          Viewing 2 reply threads
          • You must be logged in to reply to this topic.
          About the MRF Patient Forum

          The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

          The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.

          Popular Topics